MFDS designates renal cell carcinoma therapy ‘cabozantinib’ as orphan drug

Published: 2017-02-08 16:30:00
Updated: 2017-02-08 13:52:01

‘Cabozantinib,’ a progressive renal cell carcinoma treatment, will be designated as orphan drug.

The Ministry of Food and Drug Safety(MFDS) will make a pre-announcement of the ‘Partial Amendment to the Regulation for Designation of Orphan Drugs’ on the 6th, and said it will additionally designat...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean




Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.